Supreme Court Opinions

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

17 min · 7. juni 2026
episode Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. cover

Beskrivelse

Welcome to Supreme Court Opinions. In this episode, you’ll hear the Court’s opinion in Hikma Pharmaceuticals USA Inc. v Amarin Pharma, Inc. In this case, the court considered these issues. 1. When a generic drug manufacturer excludes a patented use from its label, can it still be liable for inducing infringement if it calls its product a “generic version” of the brand-name drug and cites publicly available information about the brand-name drug’s sales? 2. Can a patent infringement complaint survive dismissal if it does not allege that the defendant made any statement specifically instructing or encouraging the patented use? The case was decided on June 4, 2026.  The opinion is presented here in its entirety, but with citations omitted. If you appreciate this episode, please subscribe. Thank you.

Kommentarer

0

Vær den første til at kommentere

Tilmeld dig nu og bliv en del af Supreme Court Opinions-fællesskabet!

Kom i gang

1 måned kun 9 kr.

Derefter 99 kr. / måned · Opsig når som helst.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

Alle episoder

280 episoder